Corient Private Wealth LP Buys New Stake in Repligen Corporation $RGEN

Corient Private Wealth LP purchased a new position in shares of Repligen Corporation (NASDAQ:RGEN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,286 shares of the biotechnology company’s stock, valued at approximately $1,540,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RGEN. Measured Wealth Private Client Group LLC acquired a new position in shares of Repligen in the third quarter worth about $29,000. Los Angeles Capital Management LLC purchased a new stake in shares of Repligen during the 4th quarter worth about $36,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Repligen during the 2nd quarter valued at about $52,000. Farther Finance Advisors LLC grew its position in shares of Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 128 shares during the period. Finally, Itau Unibanco Holding S.A. increased its stake in shares of Repligen by 38.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 104 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Buying and Selling

In related news, CFO Jason Garland sold 733 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This represents a 3.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on RGEN shares. Citigroup upgraded Repligen to a “buy” rating in a research report on Tuesday, July 7th. Wells Fargo & Company lifted their price target on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Royal Bank Of Canada began coverage on shares of Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price target for the company. Zacks Research raised shares of Repligen from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 30th. Finally, Wolfe Research began coverage on shares of Repligen in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Repligen currently has an average rating of “Buy” and a consensus target price of $166.43.

Repligen Trading Down 1.9%

RGEN stock opened at $169.61 on Friday. Repligen Corporation has a 12-month low of $100.99 and a 12-month high of $188.73. The business’s 50-day moving average is $155.13 and its 200 day moving average is $134.02. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. The stock has a market cap of $9.57 billion, a price-to-earnings ratio of 232.34, a PEG ratio of 3.16 and a beta of 1.05.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, sell-side analysts anticipate that Repligen Corporation will post 2.06 EPS for the current fiscal year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.